Effect of curcumin on serum brain-derived neurotrophic factor levels in women with premenstrual syndrome: A randomized, double-blind, placebo-controlled trial

Neuropeptides

Volumn 56, Issue , 2016, Pages 25-31

  Fanaei, Hamed ^a,b   Khayat, Samira ^c,d   Kasaeian, Amir ^d,e,f   Javadimehr, Mani ^b  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Brain derived neurotrophic factor; Curcumin; Premenstrual syndrome

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CURCUMIN; GELATIN; PLACEBO; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MENSTRUAL CYCLE; MICROCAPSULE; MOOD; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SYMPTOM; ADULT; BLOOD; CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CURCUMIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PREMENSTRUAL SYNDROME; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84947596138     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2015.11.003     Document Type: Article

References (68)

1. Abbasinia K., et al. A comparative study of the effects of omega-3 and perforan on severity mood symptoms in premenstrual syndrome. Complement. Med. J. 2013, 3(3):529-540.
2. American Psychiatric Association Diagnostic criteria from DSM-IV-TR 2000, xii. American Psychiatric Association, Washington, D.C., (370 p.).
3. Angst J., et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr. Scand. 2001, 104(2):110-116.
4. Association A.P. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®) 2013, American Psychiatric Pub.
5. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 2012, 64(2):238-258.
6. Babazadeh R., Keramat A. Premenstrual syndrome and complementary medicine in Iran: a systematic review. KAUMS Journal (FEYZ) 2011, 15(2):174-187.
7. Balaratnasingam S., Janca A. Brain derived neurotrophic factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol. Ther. 2012, 134(1):116-124.
8. Beiranvand S.P., et al. The effect of Crocus sativus (Saffron) on the severity of premenstrual syndrome. Eur. J. Integrative Med. 2015.
9. Begliuomini S., et al. Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum. Reprod. 2007, 22(4):995-1002.
10. Blurton-Jones M., Kuan P.N., Tuszynski M.H. Anatomical evidence for transsynaptic influences of estrogen on brain-derived neurotrophic factor expression. J. Comp. Neurol. 2004, 468(3):347-360.
11. Borrow A.P., Cameron N.M. Estrogenic mediation of serotonergic and neurotrophic systems: implications for female mood disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014.
12. Comasco E., et al. Postpartum depressive symptoms and the BDNF Val66Met functional polymorphism: effect of season of delivery. Arch. Womens Ment. Health 2011, 14(6):453-463.
13. Comasco E., et al. Emotional fronto-cingulate cortex activation and brain derived neurotrophic factor polymorphism in premenstrual dysphoric disorder. Hum. Brain Mapp. 2014, 35(9):4450-4458.
14. Cubeddu A., et al. Paroxetine increases brain-derived neurotrophic factor in postmenopausal women. Menopause 2010, 17(2):338-343.
15. Cubeddu A., et al. Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology 2011, 36(4):523-530.
16. Dante G., Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J. Psychosom. Obstet. Gynaecol. 2011, 32(1):42-51.
17. Deltheil T., et al. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 2008, 55(6):1006-1014.
18. Epperson C.N. Premenstrual dysphoric disorder and the brain. Am. J. Psychiatry 2013, 170(3):248-252.
19. Fanaei H., et al. Testosterone enhances functional recovery after stroke through promotion of antioxidant defenses, BDNF levels and neurogenesis in male rats. Brain Res. 2014, 1558:74-83.
20. Farrokh-Eslamlou H., et al. Premenstrual syndrome and quality of life in Iranian medical students. Sex. Reprod. Healthc. 2015, 6(1):23-27.
21. Franco-Robles E., et al. Effects of curcumin on brain-derived neurotrophic factor levels and oxidative damage in obesity and diabetes. Appl. Physiol. Nutr. Metab. 2014, 39(2):211-218.
22. Freeman E.W. Therapeutic management of premenstrual syndrome. Expert. Opin. Pharmacother. 2010, 11(17):2879-2889.
23. Ghosh S., Banerjee S., Sil P.C. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem. Toxicol. 2015, 83:111-124.
24. He B.L., et al. BDNF expression with functional improvement in transected spinal cord treated with neural stem cells in adult rats. Neuropeptides 2013, 47(1):1-7.
25. He Y., et al. Curcumin, inflammation, and chronic diseases: how are they linked?. Molecules 2015, 20(5):9183-9213.
26. Hong C.J., Liou Y.J., Tsai S.J. Effects of BDNF polymorphisms on brain function and behavior in health and disease. Brain Res. Bull. 2011, 86(5-6):287-297.
27. Iughetti L., et al. Plasma brain-derived neurotrophic factor concentrations in children and adolescents. Neuropeptides 2011, 45(3):205-211.
28. Jang S.H., Kim D.I., Choi M.S. Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: systematic review. BMC Complement Altern. Med. 2014, 14:11.
29. Jarvis C.I., Lynch A.M., Morin A.K. Management strategies for premenstrual syndrome/premenstrual dysphoric disorder. Ann. Pharmacother. 2008, 42(7):967-978.
30. Khayat S., et al. Effect of treatment with ginger on the severity of premenstrual syndrome symptoms. ISRN Obstet. Gynecol. 2014, 2014:5.
31. Khayat S., et al. The effect of ginger on symptoms of premenstrual syndrome in university students. Med. Surg. Nurs. J. 2014, 3(1):10-16.
32. Kroll R., Rapkin A.J. Treatment of premenstrual disorders. J Reprod. Med. 2006, 51(4 Suppl):359-370.
33. Kumar T.P., et al. Curcumin modulates dopaminergic receptor, CREB and phospholipase C gene expression in the cerebral cortex and cerebellum of streptozotocin induced diabetic rats. J. Biomed. Sci. 2010, 17:43.
34. Kulkarni S.K., Dhir A. An overview of curcumin in neurological disorders. Indian J. Pharm. Sci. 2010, 72(2):149-154.
35. Kulkarni S., Dhir A., Akula K.K. Potentials of curcumin as an antidepressant. ScientificWorldJournal 2009, 9:1233-1241.
36. Kulkarni S.K., Bhutani M.K., Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology 2008, 201(3):435-442.
37. Lee K.H., et al. A curcumin derivative, 2,6-bis(2,5-dimethoxybenzylidene)-cyclohexanone (BDMC33) attenuates prostaglandin E2 synthesis via selective suppression of cyclooxygenase-2 in IFN-gamma/LPS-stimulated macrophages. Molecules 2011, 16(11):9728-9738.
38. Li Y.-J., et al. Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS One 2013, 8(5).
39. Liu D., et al. Effects of curcumin on learning and memory deficits, BDNF, and ERK protein expression in rats exposed to chronic unpredictable stress. Behav. Brain Res. 2014, 271:116-121.
40. Lopresti A.L., Hood S.D., Drummond P.D. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J. Psychopharmacol. 2012, 26(12):1512-1524.
41. Lopresti A.L., et al. Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change. Eur. Neuropsychopharmacol. 2015, 25(1):38-50.
42. Macedo I.C., et al. Chronic stress associated with hypercaloric diet changes the hippocampal BDNF levels in male Wistar rats. Neuropeptides 2015, 51:75-81.
43. Marjoribanks J., et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev. 2013, 6.
44. Maleki, F., et al., The Impact of Premenstrual Disorders on Health-related Quality of Life (HRQOL). BOARDS & COMMITTEES: 2014, p. 105.
45. Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008, 33(1):73-83.
46. Molendijk M.L., et al. Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. PLoS One 2012, 7(11).
47. Mythri R.B., Bharath M.M. Curcumin: a potential neuroprotective agent in Parkinson's disease. Curr. Pharm. Des. 2012, 18(1):91-99.
48. Naumenko V.S., et al. Effect of brain-derived neurotrophic factor on behavior and key members of the brain serotonin system in genetically predisposed to behavioral disorders mouse strains. Neuroscience 2012, 214:59-67.
49. Oral E., et al. Serum brain-derived neurotrophic factor differences between the luteal and follicular phases in premenstrual dysphoric disorder. Gen. Hosp. Psychiatry 2015, 37(3):266-272.
50. Ossewaarde L., et al. Menstrual cycle-related changes in amygdala morphology are associated with changes in stress sensitivity. Hum. Brain Mapp. 2013, 34(5):1187-1193.
51. Protopopescu X., et al. Hippocampal structural changes across the menstrual cycle. Hippocampus 2008, 18(10):985-988.
52. Pluchino N., et al. Daily variation of brain-derived neurotrophic factor and cortisol in women with normal menstrual cycles, undergoing oral contraception and in postmenopause. Hum. Reprod. 2009, 24(9):2303-2309.
53. Pérez-López F.R.C., Peter P.P.-R.R., Gonzalo L.L.-B.B., María T., Cuadros-López J.L. Premenstrual syndrome and premenstrual dysphoric disorder: symptoms and cluster influences. Open Psychiatry J. 2009, 3:39-49.
54. Rapkin A.J., Akopians A.L. Pathophysiology of premenstrual syndrome and premenstrual dysphoric disorder. Menopause Int. 2012, 18(2):52-59.
55. Sanmukhani J., Anovadiya A., Tripathi C.B. Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study. Acta Pol. Pharm. 2011, 68(5):769-775.
56. Seedhom A.E., Mohammed E.S., Mahfouz E.M. Life style factors associated with premenstrual syndrome among El-Minia University students, Egypt. ISRN. Public Health 2013, 2013:6.
57. Talaei A., et al. Epidemiology of premenstrual syndrome (PMS) in students of Mashhad university of medical sciences. Iran. J. Obst. Gynecol. Infertility 2009, 12(2):15-22.
58. Takeda T., et al. Premenstrual syndrome and premenstrual dysphoric disorder in Japanese collegiate athletes. J. Pediatr. Adolesc. Gynecol. 2015, 28(4):215-218.
59. Tatari F., et al. Frequency of pre-menstrual dysphoric disorder (PMDD), premenstrual syndrome (PMS) and some related factors in students of girls' high schools of Kermanshah. J. Res. Behav. Sci. 2008, 5(1):13-19.
60. ter Horst G.J. Estrogen in the limbic system. Vitam. Horm. 2010, 82:319-338.
61. Toffoletto S., et al. Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: a systematic review. Psychoneuroendocrinology 2014, 50:28-52.
62. Wichianpitaya J., Taneepanichskul S. A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. Obstet. Gynecol. Int. 2013, 2013:487143.
63. Whelan A.M., Jurgens T.M., Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can. J. Clin. Pharmacol. 2009, 16(3):e407-e429.
64. Yamamoto Y., et al. Antidepressant-like effect of food-derived pyroglutamyl peptides in mice. Neuropeptides 2015, 51:25-29.
65. Yoshimura R., et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31(5):1034-1037.
66. Zachar P., Kendler K.S. A diagnostic and statistical manual of mental disorders history of premenstrual dysphoric disorder. J. Nerv. Ment. Dis. 2014, 202(4):346-352.
67. Zaben M.J., Gray W.P. Neuropeptides and hippocampal neurogenesis. Neuropeptides 2013, 47(6):431-438.
68. Zhu Z., et al. Central expression and anorectic effect of brain-derived neurotrophic factor are regulated by circulating estradiol levels. Horm. Behav. 2013, 63(3):533-542.